Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial

Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales: Schernthaner, G., Schernthaner, G.-H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839058/
https://www.ncbi.nlm.nih.gov/pubmed/27071968
http://dx.doi.org/10.1007/s00059-016-4427-3